000			03174nam a22003975i 4500
001			100094
003			DE-He213
005			20230110040205.0
007			cr nn 008mamaa
008			180605s2018 gw | s |||| 0|eng d
020			_a9783319768793 _9
024	7		_a10.1007/978-3-319-76879-3 _2doi
040			_aES-MaUEC _bspa
050		4	_aRC645.73 2018 EB
245	1	0	_aMyelodysplastic Syndromes: _bDiagnosis - Prognosis - Therapy _cedited by Uwe Platzbecker, Pierre Fenaux.
264		1	_aCham _bSpringer International Publishing _c2018
300			_a1 recurso en línea (V, 157 páginas 26 ilustraciones, 22 ilustraciones a color)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aHematologic Malignancies _x2197-9766
505	0		_aDiagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation. .
520	3		_aThis book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
650		7	_9140122 _aHematología
650		7	_aOncología _2embne _9139207
650		7	_aMédula ósea
700	1		_aPlatzbecker, Uwe. _eeditor literario
700	1		_aFenaux, Pierre. _eeditor literario _0http://id.loc.gov/authorities/names/no2014075471 _0http://viaf.org/viaf/74029040
776	0	8	_iEdición impresa: _z9783319768786
776	0	8	_iEdición impresa: _z9783319768809
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-76879-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aMedicine (Springer-11650)
988			_aSpringer_Medicine_2018
998			_b01/2019 _dz _ep _feng _ggw _h0
999			_c100094 _d100094 _x1